CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

AstraZeneca Q3 revenue rises 7% on Oncology unit strength

By Reuters News


Overview

  • UK pharma group's Q3 revenue rose 7% yr/yr, beating analyst expectations

  • Core EPS for Q3 increased 17% and beat analyst expectations

  • Growth in Oncology, R&I and Rare Disease offset declines in some cardiovascular drugs


Outlook

  • AstraZeneca expects FY 2026 total revenue to rise by a mid-to-high single-digit percentage

  • Company forecasts FY 2026 core EPS to grow by a low double-digit percentage

  • AstraZeneca anticipates FY 2026 core tax rate between 18% and 22%


Result Drivers

  • ONCOLOGY, R&I, RARE DISEASE GROWTH - Co said double-digit growth in Oncology, Respiratory & Immunology, and Rare Disease segments offset declines in some cardiovascular drugs

  • PRODUCT MIX, PRICING PRESSURE - Gross margin benefited from positive product mix, but was partly offset by pricing headwinds and loss of exclusivity, especially in China

  • GENERIC COMPETITION - Loss of exclusivity and generic competition weighed on Farxiga and Brilinta sales


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$16.21 bln

$16.03 bln (16 Analysts)

Q3 Core EPS

Beat

$2.79

$2.59 (15 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for AstraZeneca PLC is GBp16,000.00, about 22.6% above its October 29 closing price of GBp13,052.00

  • The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago


Reuters Recommended Reads

  • Oct 28 - GSK pipeline doubts, vaccine underperformance overshadow sales beat

  • Oct 28 - Biogen Q3 revenue beats on Apellis acquisition, product demand

  • Oct 29 - Merck Q3 profit beats on Keytruda demand


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.